S

SSY Group Ltd
HKEX:2005

Watchlist Manager
SSY Group Ltd
HKEX:2005
Watchlist
Price: 3.73 HKD -2.1% Market Closed
Market Cap: 11B HKD
Have any thoughts about
SSY Group Ltd?
Write Note

SSY Group Ltd
Current Portion of Long-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

SSY Group Ltd
Current Portion of Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Current Portion of Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
S
SSY Group Ltd
HKEX:2005
Current Portion of Long-Term Debt
HK$897.2m
CAGR 3-Years
-8%
CAGR 5-Years
6%
CAGR 10-Years
26%
G
Grand Pharmaceutical Group Ltd
HKEX:512
Current Portion of Long-Term Debt
HK$2.5B
CAGR 3-Years
30%
CAGR 5-Years
6%
CAGR 10-Years
4%
U
United Laboratories International Holdings Ltd
HKEX:3933
Current Portion of Long-Term Debt
ÂĄ1B
CAGR 3-Years
-9%
CAGR 5-Years
-23%
CAGR 10-Years
-14%
Sino Biopharmaceutical Ltd
HKEX:1177
Current Portion of Long-Term Debt
ÂĄ8.5B
CAGR 3-Years
66%
CAGR 5-Years
60%
CAGR 10-Years
64%
C
China Resources Pharmaceutical Group Ltd
HKEX:3320
Current Portion of Long-Term Debt
HK$54.5B
CAGR 3-Years
-4%
CAGR 5-Years
3%
CAGR 10-Years
N/A
H
HUTCHMED (China) Ltd
HKEX:13
Current Portion of Long-Term Debt
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

SSY Group Ltd
Glance View

Market Cap
11.1B HKD
Industry
Pharmaceuticals

SSY Group Ltd. is an investment holding company, which engages in the research, development, and manufacture of pharmaceutical products. The company employs 4,800 full-time employees The company went IPO on 2005-12-20. The Company’s main products include finished medicines of mainly intravenous infusion solution to hospitals and distributors, bulk pharmaceuticals and medical materials. The Company’s products mainly include non-PVC (Polyvinyl chloride) soft bag infusion solution, PP (Polypropylene) plastic bottle infusion solution and Glass bottle infusion solution. The Company’s products also include Hydrochloride Betahistine, Hydrochloride Ambroxol and Doxofylline as well as bulk pharmaceuticals including caffeine, theophylline, aminophylline, metronidazole and nifedipine.

Intrinsic Value
5.41 HKD
Undervaluation 31%
Intrinsic Value
Price
S

See Also

What is SSY Group Ltd's Current Portion of Long-Term Debt?
Current Portion of Long-Term Debt
897.2m HKD

Based on the financial report for Jun 30, 2024, SSY Group Ltd's Current Portion of Long-Term Debt amounts to 897.2m HKD.

What is SSY Group Ltd's Current Portion of Long-Term Debt growth rate?
Current Portion of Long-Term Debt CAGR 10Y
26%

Over the last year, the Current Portion of Long-Term Debt growth was -46%. The average annual Current Portion of Long-Term Debt growth rates for SSY Group Ltd have been -8% over the past three years , 6% over the past five years , and 26% over the past ten years .

Back to Top